ArticleVaccines2025

Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age.

Joel M Neutel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.